About

Ready to Catalyze the Next Wave of Inflammasome Therapies?

The 7th Inflammasome Therapeutics Summit is your go-to forum for drug developers, translational scientists, and immunology innovators striving to push inflammasome-targeted therapies from concept to clinic. Join 70+ leaders across pharma, biotech, and academia as they converge to decode the latest clinical readouts and explore novel therapeutic avenues beyond NLRP3.

Over three action-packed days, we will unpack high-impact case studies from the front lines – covering emerging upstream and downstream targets, mechanisms beyond canonical pathways, and how these insights are unlocking new disease areas from neuroinflammation and atopic dermatitis to obesity and fibrotic conditions.

Get ready for in-depth sessions on optimizing translational models, identifying next-gen biomarkers, and mapping inflammasome signaling across diverse indications. If you are serious about leading the charge in inflammasome drug development, this is where the future takes shape.

Data-Driven Case Studies You Can’t Miss:

Uncovering the latest breakthroughs in inflammasome biology, from novel activation pathways to structural mechanisms and therapeutic implications with Pfizer, EMUNO Therapeutics, TheraVac Biologics, and Azome Therapeutic

Addressing translational challenges from preclinical models to human trials including biomarker development and patient stratification with Inflammasome Therapeutics and Neumora

Evaluating disease-specific opportunities across neuroinflammation, autoimmune and metabolic disorders, and beyond with Ventyx Biosciences, AC Immune, and ZyVersa Therapeutics

Facilitating cross-disciplinary collaborations between pharma, biotech, and academia to accelerate clinical impact and commercialization

Who Will You Meet?

This industry-definitive, inflammasome-focused forum is your golden ticket to join and network with 70+ C-Levels, Vice Presidents, and Scientific Leaders across immunology, translational research, biomarker strategy, and clinical development – all under one roof – with the shared mission of advancing inflammasome-targeted therapies.

From dissecting clinical updates to identifying novel targets beyond NLRP3, this summit brings together the brightest minds transforming the field of innate immunity and inflammation.

What Last Year’s Attendees Have to Say:

What stood out was the presence of new players in the space who showcased their early-stage programs, offering fresh perspectives.

AC Immune

Cutting-edge updates on where this field stands, with notable highlights on the CNS area and discussions around NLRP3 applications.

Schrodinger

Great to get insights from other biopharma companies with ongoing clinical trials as well as academics that had high-quality talks.

Neurocrine Biosciences